<DOC>
	<DOCNO>NCT01288521</DOCNO>
	<brief_summary>Solid organ transplant recipient would greatly benefit pharmacogenetic evaluation since immunosuppressive drug regimen consist multiple medication narrow therapeutic range toxic adverse event profile . Tacrolimus potent immunosuppressive agent utilized rejection prophylaxis . Intensive pharmacokinetic monitoring must perform follow organ transplantation ensure therapeutic drug concentration due highly variable pharmacokinetics profile narrow therapeutic index . Tacrolimus substrate CYP450 3A membrane transporter p-glycoprotein ( Pgp ) . Polymorphisms gene encode CYP3A5 extensively study found influence dose tacrolimus . The effect ABCB1 gene polymorphism ( encodes Pgp ) upon tacrolimus pharmacokinetics difficult establish . This study determine haplotype derive three frequent polymorphism ABCB1 gene ( C1236T , G2677T , C3435T ) predict degree drug interaction tacrolimus ( CYP3A5/Pgp substrate ) ketoconazole ( CYP3A5/Pgp inhibitor ) patient CYP3A5 nonexpressors . This prospective pharmacokinetic pharmacogenomic study enroll 20 stable renal transplant recipient CYP3A5 *3/*3 genotype group ABCB1 haplotype ( CGC v TTT ) . Pharmacokinetics tacrolimus assess 2 occasion without ketoconazole coadministration separate 1 week . The order study occasion randomize crossover design . The result study may identify genomic marker predict drug-drug interaction . Knowing information priori aid clinician modify drug dose alleviate patient burden significant drug toxicity .</brief_summary>
	<brief_title>Pharmacogenetics Predict Drug Interactions Kidney Transplant Recipients</brief_title>
	<detailed_description>Two mL blood obtain pharmacogenomic screening CYP3A5 ABCB1 genotype . Patients CYP3A5*3/*3 genotype consent pharmacokinetic portion study . Volunteers patient cohort participate 2 overnight visit General Clinical Research Center ( GCRC ) . Patients report GCRC evening study visit . They require fast midnight night 1 hour tacrolimus administration , morning approximately 8 . Pharmacokinetics tacrolimus assess 2 occasion without ketoconazole coadministration separate 1 week . The order study occasion randomize crossover design . Each patient take take usual oral dose tacrolimus whole blood level obtain immediately ( C0 ) 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 hour tacrolimus dose . They receive tacrolimus intravenous infusion , therapeutic dose four hour . The IV dose take place patient ' usual evening dose tacrolimus . Additional blood drawn tacrolimus 0.25 , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 6 , 8 , 12 , 18 hour intravenous dose . During ketoconazole visit , tacrolimus dos decrease one-half account drug interaction avoid potential tacrolimus-induced toxicity . Ketoconazole 200 mg administer orally every 12 hour total 3 dos ; first ketoconazole dose give 13 hour tacrolimus administration .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<criteria>Kidney transplant recipient &gt; 6 month posttransplant Serum creatinine &lt; 1.6 mg/dL Currently take stable dose tacrolims On medication know interact tacrolimus ketoconazole Multiorgan transplant recipient Serum creatinine &gt; 1.5 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>kidney transplantation</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>P-glycoprotein</keyword>
	<keyword>ABCB1</keyword>
	<keyword>genotyping</keyword>
</DOC>